Mahoney: Too much CEO turnover at Boston Scientific

January 8, 2013 by Arezu Sarvestani

New Boston Scientific CEO Michael Mahoney is in it for the long haul, he tells investors at the J.P. Morgan Healthcare conference.

Michael Mahoney headshot

There's been too much turnover in the corner office at Boston Scientific (NYSE:BSX), and Michael Mahoney aims to change that, he told an audience at the J.P. Morgan Healthcare Conference in San Francisco today.

"I'm really making a long-term commitment to the company," Mahoney said today. "I absolutely love it, I'm enjoying what I'm doing."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.